Clinical Trials Logo

Clinical Trial Summary

Antiplatelet therapy remains a cornerstone in the treatment of acute and chronic coronary artery disease. Aspirin was the first such therapy to prove its benefits in acute myocardial infarction. Compared to aspirin monotherapy, the combination of aspirin and clopidogrel, a thienopyridine P2Y12 inhibitor, has been demonstrated to reduce adverse event rates among patients with acute coronary syndromes (with or without ST-segment elevation) and those receiving intracoronary stents. In the Triton-TIMI 38 trial a novel thienopyridine, prasugrel, was compared to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Although prasugrel significantly reduced recurrent myocardial infarction, bleeding rates were increased and no improvement in cardiac or all-cause mortality was demonstrated. However, in 2009, the authors of the PLATO trial demonstrated an unexpected cardiovascular mortality benefit with ticagrelor over clopidogrel, an endpoint not previously met by any other antiplatelet agent against an active comparator. Based on the reproducible adverse events seen in the DISPERSE, DISPERSE-2, and PLATO trials, an adenosine-mediated effect of ticagrelor is proposed. Hypothesis: The aim of this study is to test the hypothesis that ticagrelor produces pharmacologic ischemic preconditioning, an undescribed potential off-label property of ticagrelor that could represent a plausible mechanism for its effects on cardiovascular mortality.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01743937
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Terminated
Phase Phase 4
Start date January 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT01235286 - Cutaneous Remote Ischemic Preconditioning in Plastic Surgery N/A
Completed NCT01118000 - Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning N/A
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Recruiting NCT03380663 - Conditioning Based Intervention Strategies N/A
Completed NCT03023150 - Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation - Froedtert N/A
Completed NCT02981680 - Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery N/A
Completed NCT00821522 - The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery Phase 1
Active, not recruiting NCT01164618 - The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response Phase 2
Not yet recruiting NCT05957523 - Effects of Remote Ischemic Preconditioning on Components of Peripheral Blood and Gut Microbiome (EMINENT) N/A
Completed NCT04887610 - Factors That Influence Blood Vessel Regulation During Exercise in Humans N/A
Completed NCT05219344 - Tissue Flossing and Lower Limb Neuromuscular Function N/A
Completed NCT00453531 - Model System for Transient Forearm Blood Vessel Dysfunction Phase 1/Phase 2
Not yet recruiting NCT05412888 - Effect of CoQ10 on the Endocrine Function of Skeletal Muscle N/A
Recruiting NCT03900390 - The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient N/A
Completed NCT02411266 - Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage N/A
Completed NCT02666235 - Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR) Phase 2
Completed NCT04016857 - Remote Ischemic Preconditioning During Lower Limb Revascularization N/A
Not yet recruiting NCT05653505 - Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
Completed NCT02965547 - Remote Ischemic Preconditioning of Dynamic Cerebral Autoregulation in Healthy Adults N/A
Completed NCT05350683 - Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR Phase 2